CStone Pharmaceuticals’ H1 2022 Revenue Jumps 229% on Drug Sales Growth
China-based CStone Pharmaceuticals (HKG: 2616) reported RMB 262 million (USD 49.4 million) in revenue for...
CStone Pharmaceuticals
EQRx Accelerates US Development of Two Chinese-Licensed Cancer Drugs
US-based pharma EQRx Inc. (Nasdaq: EQRX) has revealed its latest plans to accelerate the US...
CStone Pharmaceuticals and Kindstar Global Partner on Blood Tumor Precision Diagnosis and Treatment
China-based CStone Pharmaceuticals (HKG: 2616) announced a strategic collaboration with compatriot firm Kindstar Global (HKG:...
Pfizer Launches Cejemly in China for Stage III NSCLC, Expands Immunotherapy Reach
Pfizer announced the commercial launch of Cejemly (sugemalimab) in China for Stage III non-small cell...
CStone Pharmaceuticals’ Gavreto Wins Hong Kong Approval for RET Fusion NSCLC
CStone Pharmaceuticals (HKG: 2616) announced that its RET inhibitor Gavreto (pralsetinib) has received marketing approval...
CStone Pharmaceuticals Explores Strategic Options Including Buyout
China-based CStone Pharmaceuticals (HKG: 2616) is evaluating strategic options, including a potential buyout, according to...
CStone Pharmaceuticals’ Ayvakit Included in Taiwan’s National Health Insurance
China-based CStone Pharmaceuticals (HKG: 2616) announced that its Ayvakit (avapritinib), a tyrosine kinase inhibitor for...
Pfizer’s Lorbrena Receives First Prescription in China for NSCLC Treatment
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the first prescription of its third-generation...